1.Vascular maps with dynamic contrast-enhanced MRI for diagnosis of breast cancer
Bo YIN ; Li LIU ; Meng SHI ; Daoying GENG ; Yadi LI
Chinese Journal of General Practitioners 2009;8(10):744-745
Total 52 patients with breast lesions underwent dynamic contrast-enhanced breast MRI; and the breast vascularization was scored on the MRI vascular maps with a range of 0 to 3. The mean number of vessels per ipsilateral breast in malignant cases was higher than that of benign cases (3.8±2.0 vs. 1.3± 1.0; P=0.000). When the breast vascularity score 0-1 was defined as benign and 2-3 was defined as malignant, the sensitivity and specificity was 79% and 83%, respectively. Results indicate that dynamic contrast-enhanced breast MRI is of value in diagnosis of malignant breast lesions.
2.The application of low-dose test method combined with variable helical pitch technology in CT angiography of lower extremity arteries
Jigang GENG ; Xiaoshi LI ; Dayong JIN ; Yadi YANG ; Lu LU ; Yue QIN
Journal of Practical Radiology 2024;40(4):646-649,669
Objective To evaluate the application efficacy of low-dose test method combined with variable helical pitch(VHP)technology in computed tomography angiography(CTA)of lower extremity arteries.Methods Eighty patients with CTA imaging of bilateral lower extremity arteries were selected and divided into group A and group B on average.VHP technology was used in group A,and conventional fixed pitch scanning was used in group B.The objective and subjective image quality of the two groups were compared,and the radiation dose and contrast agent dosage of the two groups were recorded and compared.Results The subjective image quality evaluation of group A was significantly better than that of group B,and the difference was statistically significant(Kappa test,P<0.05).In the objective image quality evaluation,the CT value and signal-to-noise ratio(SNR)value of the common iliac artery,popliteal artery and anterior tibial artery in group A were higher than those in group B at the same level,and the differences were statistically significant(P<0.05);The effective dose(ED)value in group A was(6.74±1.20)mSv,and that in group B was(7.93±1.78)mSv(P<0.05).The dosage of contrast agent in group A was significantly lower than that in group B[(73.97±12.15)mL in group A,(82.50±2.61)mL in group B](P<0.05).Conclusion Low-dose test method combined with VHP technology not only can reduce the radiation dose and contrast agent dosage,but also can effectively improve the success rate and image quality of lower extremity arteries examination,which is worthy of clinical application.
3.Efficacy and safety of albumin-bound paclitaxel in the treatment of advanced non-small cell lung cancer
Peng JI ; Lijuan NING ; Yongwu CHEN ; Pengli ZHU ; Fei WU ; Yingqi WU ; Hui YAN ; Yadi GENG ; Shengyu ZHANG ; Aizong SHEN
China Pharmacy 2022;33(22):2762-2765
OBJECTIVE To observe the efficacy and safety of albumin-bound paclitaxel in the treatment of advanced non- small cell lung cancer (NSCLC). METHODS Clinical data of patients with advanced NSCLC treated in our hospital from January 2018 to December 2021 were selected. According to their chemotherapy regimen,they were divided into albumin-bound paclitaxel group and paclitaxel group, with 100 patients in each group. Both groups received chemotherapy regimen containing Paclitaxel for injection (albumin-bound) or Paclitaxel injection for at least 2 cycles (every 21 days as a cycle). The progression-free survival (PFS) and efficacy of the two groups were compared,and the occurrence of toxic and side effects were recorded. RESULTS The patients in albumin-bound paclitaxel group completed 430 cycles of chemotherapy, with an average of 4.3 cycles; patients in paclitaxel group completed 476 cycles of chemotherapy, with an average of 4.8 cycles. The median PFS (4.0 months) and the response rate (13.00%) of albumin-bound paclitaxel group were not significantly different from those of paclitaxel group (4.0 months,9.00%) (P>0.05). The disease control rate (99.00%) was significantly higher than that in paclitaxel group (89.00%), and the incidences of leukopenia, neutropenia, thrombocytopenia,anemia, sensory neuropathy, fatigue,nausea and vomiting,joint myalgia in albumin-bound paclitaxel group were significantly lower than those in paclitaxel group (P<0.05). CONCLUSIONS Albumin-bound paclitaxel is effective in the treatment of advanced NSCLC, and it can better control the progression of the disease and is safer than ordinary paclitaxel.